Literature DB >> 23198983

Isolation of viable human hepatic progenitors from adult livers is possible even after 48 hours of cold ischemia.

Sophie Aupet1, Gael Simoné, Bruno Heyd, Philippe Bachellier, Isabelle Vidal, Lysiane Richert, Hélène Martin.   

Abstract

Liver transplantation, utilized routinely for end-stage liver disease, has been constrained by the paucity of organ donors, and is being complemented by alternative strategies such as liver cell transplantation. One of the most promising forms of liver cell transplantation is hepatic stem cell therapies, as the number of human hepatic stem cells (hHpSCs) and other early hepatic progenitor cells (HPCs) are sufficient to provide treatment for multiple patients from a single liver source. In the present study, human adult livers were exposed to cold ischemia and then processed after <24 or 48 h. Cells positive for epithelial cell adhesion molecule (EpCAM), a marker on early lineage stage HPCs, were immunoselected and counted. Approximately 100,000 EpCAM(+) cells/gram of tissue was obtained from surgical resection of livers subjected to cold ischemia up to 24 h and comparable numbers, albeit somewhat lower, were obtained from those exposed to 48 h of cold ischemia. The yields are similar to those reported from livers with minimal exposure to ischemia. When cultured on plastic dishes and in Kubota's Medium, a serum-free medium designed for early lineage stage HPCs, colonies of rapidly expanding cells formed. They were confirmed to be probable hHpSCs by their ability to survive and expand on plastic and in Kubota's Medium for months, by co-expression of EpCAM and neural cell adhesion molecule, minimal if any albumin expression, with EpCAM found throughout the cells, and no expression of alpha-fetoprotein. The yields of viable EpCAM(+) cells were surprisingly large, and the numbers from a single donor liver are sufficient to treat approximately 50-100 patients given the numbers of EpCAM(+) cells currently used in hepatic stem cell therapies. Thus, cold ischemic livers for up to 48 h are a new source of cells that might be used for liver cell therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23198983     DOI: 10.1089/ten.TEC.2012.0237

Source DB:  PubMed          Journal:  Tissue Eng Part C Methods        ISSN: 1937-3384            Impact factor:   3.056


  3 in total

1.  Biological, Medical, and Other Tissue Variables Affecting Biospecimen Utilization.

Authors:  Dennis Otali; Sameer Al Diffalha; William E Grizzle
Journal:  Biopreserv Biobank       Date:  2019-06       Impact factor: 2.300

Review 2.  Effects of Cold Ischemia on Gene Expression: A Review and Commentary.

Authors:  William E Grizzle; Dennis Otali; Katherine C Sexton; Daniel S Atherton
Journal:  Biopreserv Biobank       Date:  2016-08-23       Impact factor: 2.300

Review 3.  EpCAM and the biology of hepatic stem/progenitor cells.

Authors:  Laurent Dollé; Neil D Theise; Eva Schmelzer; Luke Boulter; Olivier Gires; Leo A van Grunsven
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-04       Impact factor: 4.052

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.